**Beta-blocker use in acute myocardial infarction – a Cochrane systematic review which affirms routine clinical practice**

**References**

1. Safi, S. *et al.* Beta-blockers for suspected or diagnosed acute myocardial infarction. *Cochrane Database Syst. Rev.* (2019). doi:10.1002/14651858.CD012484

2. Washburn, M. F. & Cannon, W. B. Bodily Changes in Pain, Hunger, Fear, and Rage. *J. Philos. Psychol. Sci. Methods* (1917). doi:10.2307/2013624

3. Brodde, O. E. & Michel, M. C. Adrenergic and muscarinic receptors in the human heart. *Pharmacol. Rev.* **51**, 651–90 (1999).

4. Ahlquist, R. P. A study of the adrenotropic receptors. *Am. J. Physiol.* **153**, 586–600 (1948).

5. Black, J. W., Crowther, A. F., Shanks, R. G., Smith, L. H. & Dornhorst, A. C. A new adrenergic beta-receptor antagonist. *Lancet* **1**, 1080–1 (1964).

6. Quirke, V. Putting theory into practice: James Black, receptor theory and the development of the beta-blockers at ICI, 1958-1978. *Med. Hist.* **50**, 69–92 (2006).

7. Zhu, W., Woo, A. Y. H., Zhang, Y., Cao, C. M. & Xiao, R. P. β-Adrenergic Receptor Subtype Signaling in the Heart: From Bench to the Bedside. *Curr. Top. Membr.* **67**, 191–204 (2011).

8. Moniotte, S. *et al.* Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. *Circulation* **103**, 1649–55 (2001).

9. Bristow, M. R. *et al.* β1- and β2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: Coupling of both receptor subtypes to muscle contraction and selective β1-receptor down-regulation in heart failure. *Circ. Res.* **59**, 297–309 (1986).

10. Ibanez, B. *et al.* 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur. Heart J.* **39**, 119–77 (2018).

11. Timolol-Induced Reduction in Mortality and Reinfarction in Patients Surviving Acute Myocardial Infarction. *N. Engl. J. Med.* **304**, 801–7 (1981).

12. Friedman, L. M. A Randomized Trial of Propranolol in Patients With Acute Myocardial Infarction: I. Mortality Results. *JAMA J. Am. Med. Assoc.* **247**, 1707–14 (1982).

13. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. *Lancet* **2**, 57–66 (1986).

14. Roffi, M. *et al.* 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur. Heart J.* (2016). doi:10.1093/eurheartj/ehv320

15. O’Gara, P. *et al.* ACCF/AHA guideline for the management of ST-elevation myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J. Am. Coll. Cardiol.* **61**, 78–140 (2013).

16. Yang, E. H., Brilakis, E. S., Reeder, G. S. & Gersh, B. J. Modern Management of Acute Myocardial Infarction. *Curr. Probl. Cardiol.* **31**, 769–817 (2006).

17. Kontos, M. C. *et al.* Treatment and outcomes in patients with myocardial infarction treated with acute β-blocker therapy: Results from the American College of Cardiology’s NCDR®. *Am. Heart J.* **161**, 864–70 (2011).